Compare Ecolab Inc. (ECL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs GeneDx Holdings Corp — how do they compare? Ecolab Inc. trades at $281.42 (market cap $78.97B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Ecolab Inc. is far larger — about 39.1× GeneDx Holdings Corp's market cap, and Ecolab Inc. pays a 1.04% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and GeneDx Holdings Corp for 19 Days on average.
| ECL | WGS | |
|---|---|---|
Market Cap | $78.97B | $2.02B |
Volume | 974,947 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $167.51 |
52-Week Low | $245.73 | $34.51 |
Typical Hold Time | 90 Days | 19 Days |
Enterprise Value | $87.75B | $2.05B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $282.21, up 1.48% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $16.08B, net income of $2.08B, and a 12.57% net margin. Recent news highlights its dividend aristocrat status and growth in high-tech segments, while institutional buying and insider purchases reflect confidence.
Outlook is positive given earnings beats, dividend reliability, and strategic expansions like the CoolIT deal, though rising debt and cost pressures pose risks. With a consensus price target of $326.38 implying 16% upside, ECL offers growth potential but requires monitoring of leverage and execution.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
